Maxim Group set a $7.00 price objective on Can Fite Biopharma (NYSEAMERICAN:CANF) in a research note published on Monday, December 18th. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages also recently issued reports on CANF. HC Wainwright reissued a buy rating on shares of Can Fite Biopharma in a report on Tuesday, October 31st. ValuEngine downgraded shares of Can Fite Biopharma from a sell rating to a strong sell rating in a report on Thursday, September 7th.
Can Fite Biopharma (NYSEAMERICAN CANF) traded up $0.06 during mid-day trading on Monday, hitting $1.88. 192,092 shares of the stock traded hands, compared to its average volume of 261,167. The stock has a market cap of $25.30, a P/E ratio of 6.24 and a beta of 1.37. Can Fite Biopharma has a fifty-two week low of $1.24 and a fifty-two week high of $2.67.
WARNING: This story was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://ledgergazette.com/2018/01/13/maxim-group-analysts-give-can-fite-biopharma-canf-a-7-00-price-target.html.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.